Physician profile
Kokab Saeed
NPI 1447342126
$1,146.50
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $166 · 2021: $329 · 2022: $294.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $230.54 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $186.24 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.58 | 2020-2022 | |
| Corium, LLC | $129.94 | 2022 | |
| Adlon Therapeutics L.P. | $111.53 | 2019-2021 | |
| Neos Therapeutics, Lp | $111.04 | 2019-2022 | |
| Alkermes, INC. | $82.92 | 2019-2022 | |
| Orexo US, INC. | $42.53 | 2019 | |
| Noven Therapeutics, LLC | $23.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.28 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.34 | 2019 | |
| Mdd US Operations, LLC | $17.58 | 2020 | |
| Phadia US INC. | $16.66 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.08 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kokab Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.